New antisense oligonucleotide therapies reach first base in ALS

被引：0
|
作者：
Elia R. Lopez
William F. Borschel
Bryan J. Traynor
机构：
[1] National Institutes of Health,Therapeutic Development Branch, National Center for Advancing Translational Sciences
[2] National Institutes of Health,Laboratory of Neurogenetics, National Institute on Aging
来源：
Nature Medicine | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Two studies highlight the evolution of antisense oligonucleotide therapy for amyotrophic lateral sclerosis, offering hope for an effective treatment.
引用
收藏
页码：25 / 27
页数：2
相关论文
共 50 条
  • [21] Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
    Frazier, Kendall S.
    TOXICOLOGIC PATHOLOGY, 2015, 43 (01) : 78 - 89
  • [22] CHEMISTS CREATE NEW OLIGONUCLEOTIDE ANALOGS FOR ANTISENSE APPLICATIONS
    BAUM, R
    CHEMICAL & ENGINEERING NEWS, 1994, 72 (16) : 21 - 22
  • [23] Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics
    Jesper R. Nilsson
    Tom Baladi
    Audrey Gallud
    Dženita Baždarević
    Malin Lemurell
    Elin K. Esbjörner
    L. Marcus Wilhelmsson
    Anders Dahlén
    Scientific Reports, 11
  • [24] Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics
    Nilsson, Jesper R.
    Baladi, Tom
    Gallud, Audrey
    Bazdarevic, Dzenita
    Lemurell, Malin
    Esbjorner, Elin K.
    Wilhelmsson, L. Marcus
    Dahlen, Anders
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] Antisense oligonucleotide (fomivirsen sodium) treatment of CMV retinitis unresponsive to other antiviral therapies
    Lieberman, R
    Antoszyk, A
    Boyer, D
    Danis, R
    Duker, J
    Fish, R
    Goldstein, D
    Johnson, D
    Kuppermann, B
    Lambert, M
    Mansour, S
    Palestine, A
    Park, S
    Terry, B
    Vrabec, T
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 4277 - 4277
  • [26] Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
    Miller, Timothy
    Cudkowicz, Merit
    Shaw, Pamela J.
    Andersen, Peter M.
    Atassi, Nazem
    Bucelli, Robert C.
    Genge, Angela
    Glass, Jonathan
    Ladha, Shafeeq
    Ludolph, Albert L.
    Maragakis, Nicholas J.
    McDermott, Christopher J.
    Pestronk, Alan
    Ravits, John
    Salachas, Francois
    Trudell, Randall
    Van Damme, Philip
    Zinman, Lorne
    Bennett, C. Frank
    Lane, Roger
    Sandrock, Alfred
    Runz, Heiko
    Graham, Danielle
    Houshyar, Hani
    McCampbell, Alexander
    Nestorov, Ivan
    Chang, Ih
    McNeill, Manjit
    Fanning, Laura
    Fradette, Stephanie
    Ferguson, Toby A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (02): : 109 - 119
  • [27] Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases
    Giulietta Riboldi
    Chiara Zanetta
    Michela Ranieri
    Monica Nizzardo
    Chiara Simone
    Francesca Magri
    Nereo Bresolin
    Giacomo P. Comi
    Stefania Corti
    Molecular Neurobiology, 2014, 50 : 721 - 732
  • [28] Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases
    Riboldi, Giulietta
    Zanetta, Chiara
    Ranieri, Michela
    Nizzardo, Monica
    Simone, Chiara
    Magri, Francesca
    Bresolin, Nereo
    Comi, Giacomo P.
    Corti, Stefania
    MOLECULAR NEUROBIOLOGY, 2014, 50 (03) : 721 - 732
  • [29] Carbohydrate modifications in antisense oligonucleotide therapy: New kids on the block
    Manoharan, M
    Kawasaki, AM
    Prakash, TP
    Fraser, AS
    Prhavc, M
    Inamati, GB
    Casper, MD
    Cook, PD
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1999, 18 (6-7): : 1737 - 1746
  • [30] Antisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects
    Rigo, Frank
    Seth, Punit P.
    Bennett, C. Frank
    SYSTEMS BIOLOGY OF RNA BINDING PROTEINS, 2014, 825 : 303 - 352
12345